Theriva Biologics, Inc. 2026: Revenue ($3.35M), Net income ($3.22M), EPS ($0.07) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Theriva Biologics reported Q2 2026 results showing a narrowed net loss of $3.22M, up from $13.06M prior year. The company is advancing its oncology pipeline, including VCN-01 for pancreatic cancer, following positive FDA feedback. With limited cash runway, Theriva is pursuing partnerships, out-licensing, and ATM equity sales to fund clinical programs while pausing SYN-004 development.
Theriva Biologics, Inc. reported results for the 2026 quarter showing a narrower comprehensive loss and net loss versus the prior-year quarter as the company advances its oncology-focused pipeline and pursues funding and partnerships to support upcoming clinical programs.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | ($3.35M) | ($11.74M) | 71.5% |
| Net income² | ($3.22M) | ($13.06M) | 75.4% |
| Diluted EPS³ | ($0.07) | ($1.93) | 96.4% |
¹ Reported as “Total comprehensive loss”. ² Reported as “Net Loss Attributable to Common Stockholders”. ³ Reported as “Diluted loss Per Share - Basic and Dilutive”.
Business Highlights
- Regulatory progress: Positive FDA End-of-Phase 2 feedback supporting a Phase 3 design for VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC) with an adaptive, repeat-dosing plan.
- Clinical momentum: VIRAGE Phase 2b showed improved overall and progression-free survival with two VCN-01 doses; a follow-up study, VIRAGE2, was authorized to evaluate increased dosing frequency.
- Strategic focus: Following the Theriva acquisition, the company has shifted priority to oncology programs, pausing SYN-004 development absent partner funding and pursuing out-licensing for SYN-020.
- Data and translational signals: Published head-and-neck cancer (HNSCC) Phase 1 results demonstrated immune activation, PK/biomarker signals and potential resensitization to durvalumab.
- Funding actions: Management notes limited cash runway and is pursuing partnerships, out-licensing and at-the-market (ATM) equity sales to fund prioritized clinical and manufacturing activities.
Original SEC Filing: Theriva Biologics, Inc. [ TOVX ] - 10-Q - Aug. 11, 2026